OakChart

Pasithea Therapeutics Corp

KTTAHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:56 PM ET

0.5320-0.0418 (-7.28%)
2026-11-12 02:11 CET
Market cap
19.17 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-21.29 USD m
Free cash flow, TTM
-17.78 USD m
EPS diluted, TTM
-1.58
P/E
-
Compare

Price

KTTA against its 20, 50 and 200-day averages
2050200earnings
0.400.600.8013.0M26.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26KTTAclose 0.5320-day 0.4550-day 0.48200-day 0.620.53

74.2% under the 52-week high of 2.06 on 28 Nov 2025. 52-week low 0.28 on 21 Nov 2025. Last 15 sessions, 77.1% high to low

Volume 0.42× normal · the line is the 50-bar volume average

Profile

KTTA
52-week range, 14% of the way up
0.282.06

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Lawrence J. Steinman on May 12, 2020 and is headquartered in Miami Beach, FL.

Employees5
IPOSep 15, 2021
Beta0.35
ATR, 14d0.06
Rel volume0.42
Short float1.20%
Insider own3.59%
Inst own54.62%

Snapshot

6 groups

Valuation

Index-
Market Cap17.77M
Enterprise Value-28.00M
Income-21.29M
Sales0.00M
Book/sh1.49
Cash/sh1.37
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees5
IPOSep 15, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.36
P/C0.39
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio26.25
Current Ratio26.25
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.58
EPS next Y-0.46
EPS next Q-0.21
EPS this Y73.88%
EPS next Y39.47%
EPS next 5Y42.61%
EPS past 3/5Y35.92% -117.71%
Sales past 3/5Y- -
EPS Y/Y TTM79.07%
Sales Y/Y TTM-
EPS Q/Q75.06%
Sales Q/Q-
EarningsSep 02
EPS/Sales Surpr.0.00% -

Ownership

Insider Own3.59%
Insider Trans9.09%
Inst Own54.62%
Inst Trans1.28%
ROA-61.97%
ROE-65.49%
ROIC-42.72%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2016.98%
SMA5010.29%
SMA200-13.78%
Trades-

Technical

Shs Outstand33.41M
Shs Float32.21M
Short Float1.20%
Short Ratio0.64
Short Interest0.39M
52W High2.06 -74.17%
52W Low0.28 89.32%
Volatility13.57% 15.56%
ATR (14)0.06
RSI (14)57.69
Beta0.35
Rel Volume0.42
Avg Volume603.28K
Volume250,651

Performance

Perf Week0.38%
Perf Month25.53%
Perf Quarter11.30%
Perf Half Y-32.23%
Perf YTD-58.76%
Perf Year-25.07%
Perf 3Y-92.83%
Perf 5Y-98.86%
Perf 10Y-
Recom1.00
Target Price3.00
Prev Close0.57
Price0.53
Change %-7.28%

Peers

Mkt cap
TickerCompanyMkt cap
ERASErasca Inc5.88B
BDTXBlack Diamond Therapeutics Inc92.50M
OKUROnKure Therapeutics Inc136.09M
ACTUActuate Therapeutics Inc16.63M
KZIAKazia Therapeutics Limited ADR84.92M
BOLDBoundless Bio Inc55.96M
TYRATyra Biosciences Inc1.44B
MBRXMoleculin Biotech Inc8.50M
PRLDPrelude Therapeutics Inc301.66M
CRISCuris Inc3.95M

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Coastlands Capital LP10% OwnerJun 17 '26Buy0.53100,00053,0003,835,035Jun 22 10:30 AM
STEINMAN LAWRENCEDirectorNov 28 '25Buy0.75133,333100,000199,691Dec 01 09:07 AM
Marques TiagoChief Executive OfficerNov 28 '25Buy0.7533,33325,00073,334Dec 01 08:56 AM
Dumesnil SimonDirectorNov 28 '25Buy0.7533,33325,00035,833Dec 01 08:54 AM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 198
  • Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF) (GlobeNewswire) +44.02%
  • Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026 (GlobeNewswire) -5.95%
  • Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026 (GlobeNewswire) -9.05%
  • Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference (GlobeNewswire)
  • Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences (GlobeNewswire)
  • Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026 (GlobeNewswire)
  • Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit (GlobeNewswire)
  • Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion (GlobeNewswire)
  • Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial (GlobeNewswire) -8.93%
  • Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference (GlobeNewswire) -5.26%
  • Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire) -9.79%
  • Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
  • Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) (GlobeNewswire)
  • Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-02-0.160-0.160-0.000.001
2026Q12026-06-03-0.120-0.120-0.000.001
2025Q42026-02-25-0.790-0.180-0.8900.000.001
2025Q32025-12-03-0.410--0.4080.00--
2022Q42023-03-01-3.600-3.400-3.9300.200.301
2022Q32023-01-29-3.400--3.4550.20-1
2022Q22022-08-31-2.200-2.200-2.2680.000.001
2022Q12022-07-05-1.400--1.3680.00-1
2021Q42022-03-02-1.000-0.5480.100.101
2021Q32021-12-13-3.400--2.3110.00--
2026Q3---0.210--0.001
2026Q4---0.250--0.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-4.200--1.8890.000.10
2022FY-11.000--11.0400.50-
2025FY-2.910-1.500-0.000.00
2026FY--0.760--0.00
2027FY--0.460--0.00
2028FY--0.550--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-021000.000.000.00
2026Q3S2026-06-031000.000.000.00
2026Q3S2026-03-301000.000.000.00
2026Q3E2026-09-02100-0.21-0.21-0.21
2026Q3E2026-08-02100-0.21-0.21-0.21
2026Q3E2026-06-03110-0.21-0.21-0.21
2026Q3E2026-05-19110-0.21-0.21-0.21
2026Q3E2026-03-30100-0.48-0.48-0.48
2026Q2S2026-06-031000.000.000.00
2026Q2S2026-03-301000.000.000.00
2026Q2E2026-08-02100-0.16-0.16-0.16
2026Q2E2026-06-03110-0.16-0.16-0.16
2026Q2E2026-05-19110-0.16-0.16-0.16
2026Q2E2026-03-30100-0.45-0.45-0.45

Estimate history

EPS, annual-0.059-1.889-11.04-13.013-12.686-2.905-1.5797
Period202020212022202320242025TTM
EPS, quarterly-3.706-2.873-2.404-1.611-0.659-0.408-0.89-0.118-0.164
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00.01500000
Period202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.6891.151.3021.0421.39423.09133.414
Period202020212022202320242025MRQ
Shares, quarterly1.0441.0451.3942.7057.4447.44423.09124.9433.414
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.000.000.000.000.000.020.00
Cost of Goods Sold Incl. D&A0.650.660.650.650.010.020.00
Gross Profit-0.65-0.66-0.65-0.65-0.01-0.000.00
Selling, General and Administrative Excl. Other23.3016.0313.6015.3312.584.510.04
Research and Development10.737.987.208.102.67--
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-23.96-16.69-14.25-15.98-12.59-4.51-0.04
Interest Expense-0.00--0.000.000.00
Unusual Expense-1.194.460.08-0.06-0.86-2.330.00
Net Income Before Taxes-21.29-20.43-13.90-15.51-11.73-2.17-0.04
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-21.29-20.43-13.90-15.51-11.73-2.17-0.04
Net Income From Continuing Operations-21.29-20.43-13.90-15.51-11.73-2.17-0.04
Net Income-21.29-20.43-13.90-15.96-13.94-2.17-0.04
EPS (Recurring)-0.69-2.46-12.64-13.05-11.52-3.31-0.06
EPS (Basic, Before Extraordinaries)-1.58-2.91-12.69-13.01-11.04-1.89-0.06
EPS (Diluted)-1.58-2.91-12.69-13.01-11.04-1.89-0.06
EBITDA-23.30-16.03-13.60-15.33-12.58-4.51-0.04
Non-Operating Income (Expense)1.470.730.420.420.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense0.610.300.650.590.550.47-
Price To Sales Ratio----33.302,703.81-
Gross Margin------14.69-
Operating Margin------29,925.73-
Net Margin------14,430.49-
Shares Outstanding33.4123.091.391.041.301.150.69
Market Capitalization19.1719.173.997.7117.0440.7225.23

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.160.160.160.180.160.160.160.16
Gross Profit-0.16-0.16-0.16-0.18-0.16-0.16-0.16-0.16
Selling, General and Administrative Excl. Other5.564.7210.102.933.653.523.102.84
Research and Development3.692.942.741.362.151.731.511.58
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.71-4.88-10.26-3.11-3.81-3.68-3.26-3.00
Interest Expense0.000.000.00-----
Unusual Expense-0.02-1.540.42-0.050.01-0.08-0.000.07
Net Income Before Taxes-5.27-2.87-10.11-3.04-3.72-3.56-3.18-3.00
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-5.27-2.87-10.11-3.04-3.72-3.56-3.18-3.00
Net Income From Continuing Operations-5.27-2.87-10.11-3.04-3.72-3.56-3.18-3.00
Net Income-5.27-2.87-10.11-3.04-3.72-3.56-3.18-3.00
EPS (Recurring)-0.16-0.16-0.86-0.41-0.66-1.64-2.40-2.83
EPS (Basic, Before Extraordinaries)-0.16-0.12-0.89-0.41-0.66-1.61-2.40-2.87
EPS (Diluted)-0.16-0.12-0.89-0.41-0.66-1.61-2.40-2.87
EBITDA-5.56-4.72-10.10-2.93-3.65-3.52-3.10-2.84
Non-Operating Income (Expense)0.420.470.560.030.100.040.080.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.330.140.090.050.060.100.100.12
Shares Outstanding33.4124.9423.097.447.442.711.391.04
Market Capitalization19.1717.1328.895.455.373.523.995.66

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments55.266.9216.3333.0952.970.24
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.200.450.360.990.330.00
Total Current Assets56.467.3716.6934.0853.300.25
Net Property, Plant & Equipment0.000.120.220.630.020.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets3.788.579.209.830.000.00
Other Assets0.000.000.000.640.000.00
Total Assets60.2416.0626.1245.1853.320.25
Short Term Debt Incl. Current Port. of LT Debt0.000.000.080.160.000.00
Accounts Payable1.130.000.000.000.000.00
Other Current Liabilities3.841.122.551.720.450.01
Total Current Liabilities4.971.122.631.880.450.01
Long Term Debt0.000.000.000.340.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.050.160.080.461.450.00
Total Liabilities5.021.282.722.681.900.01
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity55.2214.7823.4042.5051.420.24
Total Shareholders Equity55.2214.7823.4042.5051.420.24
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity55.2214.7823.4042.5051.420.24
Total Liabilities & Stockholders Equity60.2416.0626.1245.1853.320.25
Book Value Per Share2.3910.6022.4632.6444.700.35
Tangible Book Value Per Share2.234.4513.6325.0944.700.35
Full-Time Employees548153-
Price to Book Ratio0.380.180.270.360.791.53
Return on Assets-53.54-65.93-43.50-23.81-8.11-
Return on Equity-58.36-72.83-47.07-24.97-8.41-
Return on Invested Capital-36.99-94.06-68.22-32.53-4.23-16.98
Quick Ratio11.356.586.3418.15119.1737.55
Current Ratio11.356.586.3418.15119.1737.55

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-21.29-20.43-13.90-15.51-11.73-2.17-0.04
Depreciation0.650.660.650.650.010.00-
Other Funds (Non Cash)3.684.870.85-0.14-2.81-1.110.00
Funds from Operations-16.95-14.89-12.40-15.00-14.54-3.29-0.04
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-0.83-0.32-1.521.570.850.110.00
Cash from Operating Activities-17.78-15.21-13.92-13.43-13.69-3.17-0.04
Capital Expenditures0.000.000.00-0.03-0.11-0.020.00
Net Assets From Acquisitions0.000.000.000.00-2.190.000.00
Sale of Fixed Assets and Businesses0.010.010.000.110.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.00
Other Uses0.000.000.000.00-0.630.000.00
Other Sources0.000.000.000.320.000.000.00
Cash from Investing Activities0.010.010.000.40-2.93-0.020.00
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock56.4763.974.52-3.730.0048.930.28
Repurchase of Common Pref Stock0.000.000.00-3.730.000.000.00
Sale of Common Pref Stock56.4763.974.520.000.0048.930.28
Proceedsfrom Stock Options55.4961.72-0.480.000.0048.930.28
Issuance or Reduction of Debt, Net0.290.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.45-0.450.000.00-3.217.000.00
Other Financing Activities Uses-0.45-0.450.000.00-3.210.000.00
Cash from Financing Activities56.3163.524.52-3.73-3.2155.930.28
Exchange Rate Effect0.000.02-0.00-0.000.01-0.01-
Net Change in Cash38.5548.34-9.41-16.76-19.8152.720.24
Free Cash Flow-17.78-15.21-13.92-13.46-13.80-3.20-0.04
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments45.7750.5055.264.227.225.34
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.482.231.201.311.420.78
Total Current Assets48.2452.7356.465.538.646.12
Net Property, Plant & Equipment0.000.000.000.000.110.12
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets3.473.623.788.108.268.42
Other Assets0.000.000.000.000.000.00
Total Assets51.7156.3560.2413.6317.0114.66
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.040.160.27
Accounts Payable1.841.491.131.341.581.33
Other Current Liabilities0.000.003.84-0.00-0.000.00
Total Current Liabilities1.841.494.971.381.741.59
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.030.050.050.050.090.09
Total Liabilities1.871.545.021.421.831.68
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity49.8454.8155.2212.2115.1812.98
Total Shareholders Equity49.8454.8155.2212.2115.1812.98
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity49.8454.8155.2212.2115.1812.98
Total Liabilities & Stockholders Equity51.7156.3560.2413.6317.0114.66
Book Value Per Share1.492.202.391.642.044.80
Tangible Book Value Per Share1.392.052.230.550.931.69
Full-Time Employees--5---
Price to Book Ratio0.380.310.790.360.150.12
Return on Assets-61.97-55.58-53.54-83.64-77.62-73.42
Return on Equity-65.49-58.22-58.36-89.90-85.84-82.81
Return on Invested Capital-10.58-5.24-18.31-24.88-24.48-27.45
Quick Ratio26.2535.4011.354.024.973.84
Current Ratio26.2535.4011.354.024.973.84

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-5.27-2.87-10.11-3.04-3.72-3.56
Depreciation0.160.160.160.180.160.16
Other Funds (Non Cash)0.31-1.404.670.110.070.03
Funds from Operations-4.81-4.11-5.29-2.75-3.49-3.37
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.10-0.67-0.11-0.14-0.380.32
Cash from Operating Activities-4.71-4.79-5.40-2.89-3.87-3.06
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.010.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.010.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.010.0056.460.005.851.65
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.010.0056.460.005.851.65
Proceedsfrom Stock Options0.000.0055.490.004.571.65
Issuance or Reduction of Debt, Net0.000.000.41-0.12-0.11-0.18
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-0.450.000.000.00
Other Financing Activities Uses0.000.00-0.450.000.000.00
Cash from Financing Activities0.010.0056.42-0.125.741.47
Exchange Rate Effect-0.040.030.000.010.010.00
Net Change in Cash-4.74-4.7651.04-2.991.88-1.58
Free Cash Flow-4.71-4.79-5.40-2.89-3.87-3.06

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.20%0.4M32.2M230.57K
2026-10-150.54%0.2M32.2M217.56K
2026-09-300.50%0.2M32.2M266.05K
2026-09-150.84%0.3M32.2M701.80K
2026-08-310.94%0.3M32.2M732.51K
2026-08-140.79%0.3M32.2M782.45K
2026-07-310.64%0.2M30.6M812.93K
2026-07-150.79%0.2M30.6M820.99K
2026-06-300.94%0.3M30.6M953.67K
2026-06-151.02%0.3M30.6M510.99K
2026-05-290.93%0.3M29.6M454.76K
2026-05-151.00%0.3M29.6M413.18K
2026-04-301.22%0.3M21.9M374.79K
2026-04-151.04%0.2M21.9M329.72K
2026-03-310.56%0.1M21.9M160.02K
2026-03-130.96%0.2M20.3M233.15K
2026-02-270.86%0.2M20.3M3.23M
2026-02-130.90%0.2M20.3M7.16M
2026-01-301.18%0.3M22.4M7.15M
2026-01-151.64%0.4M22.4M7.03M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06SCHEDULE 13G/ASEC
2026-09-1625-NSESEC
2026-09-168-KCurrent report2026-09-16SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-08-218-KCurrent report2026-08-20SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-07ARSAnnual report to security holders. 2025-12-31SEC
2026-08-07DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-09SEC
2026-07-31SCHEDULE 13G/ASEC
2026-07-29PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-29SEC
2026-07-01SCHEDULE 13G/ASEC
2026-06-23SCHEDULE 13GSEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-054Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-054Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-054Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-054Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-054Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-054Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-054Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-053Initial statement of beneficial ownership of securities2026-05-01SEC
2026-05-048-KCurrent report2026-05-01SEC
2026-04-22SCHEDULE 13GSEC
2026-04-173Initial statement of beneficial ownership of securities2026-04-09SEC
2026-04-08SCHEDULE 13GSEC
2026-03-3010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-27SCHEDULE 13GSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-0653.00K100
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-11150.00K300

Institutional holders

Manager% owned
Cable Car Capital, LP8.98%
Stonepine Capital Management, LLC6.59%
ADAGE CAPITAL PARTNERS GP, L.L.C.6.28%
Jupiter Topco LLC6.28%
Opaleye Management Inc.6.14%
AMERIPRISE FINANCIAL INC5.58%
AdvisorShares Investments LLC3.47%
Squadron Capital Management LLC2.99%
Vivo Capital, LLC1.39%
Persistent Asset Partners Ltd0.87%

Funds

Fund% owned
AdvisorShares Psychedelics ETF2.81%
VANGUARD EXTENDED MARKET INDEX FUND0.38%
Fidelity Extended Market Index Fund0.17%
Fidelity Nasdaq Composite Index Fund0.04%
Fidelity Series Total Market Index Fund0.02%

OakChart. KTTA. Cached 15 minutes.

Some panels did not load: ratings.